Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity and Safety of Boostrix New Syringe Presentation in Adolescents
NCT01362322Phase 4Completed
- Sponsor
- GSK
- Start
- Jul 2011
- Primary completion
- Sep 2012
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 2
01
Overview
A Phase 4 trial of Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated) in diphtheria, Tetanus, pertussis, sponsored by GSK. Started Jul 2011; status: completed.
02
Drugs
Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated)
03
Conditions
diphtheriaTetanuspertussis
Beyond the preview
Go deeper on NCT01362322.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01362322.